Jiudian Pharmaceutical announced that in the first three quarters of 2026, it achieved operating income of 2,049 billion yuan, a year-on-year decrease of 9.67%; net profit attributable to shareholders of listed companies was 240 million yuan, a year-on-year decrease of 40.96%; after deducting non-net profit of 230 million yuan, a year-on-year decrease of 41.22%. The third quarter of 2026 achieved operating income of 762 million yuan, an increase of 0.77% year on year; net profit to mother was 80.2402 million yuan, down 30.19% year on year. The decline in performance was mainly due to a year-on-year increase in the procurement price of the leading product loxoprofen sodium gel patch, management costs and financial expenses.

Jiudian Pharmaceutical announced that in the first three quarters of 2026, it achieved operating income of 2,049 billion yuan, a year-on-year decrease of 9.67%; net profit attributable to shareholders of listed companies was 240 million yuan, a year-on-year decrease of 40.96%; after deducting non-net profit of 230 million yuan, a year-on-year decrease of 41.22%. The third quarter of 2026 achieved operating income of 762 million yuan, an increase of 0.77% year on year; net profit to mother was 80.2402 million yuan, down 30.19% year on year. The decline in performance was mainly due to a year-on-year increase in the procurement price of the leading product loxoprofen sodium gel patch, management costs and financial expenses.